Market research
HOTH Hoth Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 26M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- 0.58
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US44148G2049
- Market cap
- 26M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- 0.58
About
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is based in Hoboken, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HOTH discussion.
5 years, 4 months ago
Hoth Therapeutics, Inc is currently in a long term downtrend where the price is trading 24.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Hoth Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 80.7% to $-757K since the same quarter in the previous year.
Finally, its free cash flow grew by 52.9% to $-717K since the same quarter in the previous year.
Based on the above factors, Hoth Therapeutics, Inc gets an overall score of 3/5.